Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies
October 16-18, 2008
New York, New York
The Waldorf=Astoria
CONTINUING MEDICAL EDUCATION
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 17.0 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
WHO SHOULD ATTEND
This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.
OBJECTIVES
After attending this educational activity, participants should be able to:
- Use a risk-adapted approach to assimilate current and emerging therapies in achieving complete responses in multiple myeloma
-
Review the current role of transplant in myeloma with the advent of successful novel therapies
-
Describe the strengths and weaknesses of bisphosphonate therapy in myeloma
-
Discuss the chemistry of nucleoside analogs and its relevance to frontline therapy in CLL
-
Incorporate targeted therapies and transplantation for improved patient response in CLL
-
Discuss the function of PET in Hodgkin's and non-Hodgkin's lymphoma
-
Review the approach to primary CNS lymphoma and early stage Hodgkin's
-
Employ new strategies and agents for treatment of indolent lymphoma
-
Discuss the effectiveness of radioimmunotherapies with monoclonal antibodies to treat patients with relapsed/refractory NHL
-
Discuss the most important highlights from the 10th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland
-
Evaluate lymphoma and myeloma agents in early clinical development for potential to improve upon current therapeutic outcome(s)
Lauren E. Abrey, MD Kenneth C. Anderson, MD, MA Bart Barlogie, MD, PhD James R. Berenson, MD P. Leif Bergsagel, MD, FRCP Joseph R. Bertino, MD Franco Cavalli, MD Amy Chadburn, MD Ajai Chari, MD Selina Chen-Kiang, PhD Bruce D. Cheson, MD |
Morton Coleman, MD (Chair) Rebecca Elstrom, MD Scott Ely, MD Stephen J. Forman, MD Jonathan Friedberg, MD Richard R. Furman, MD (Co-Chair) Varsha Gandhi, PhD Irene M. Ghobrial, MD Sergio Giralt, MD Jean-Luc Harousseau, MD |
Neil E. Kay, MD John P. Leonard, MD (Co-Chair) Brian K. Link, MD Isidore Lossos, MD Cynthia M. Magro, MD Tomer Mark, MD Ari M. Melnick, MD Gareth J. Morgan, MD Ruben Niesvizky, MD (Co-Chair) |
Thursday, October 16, 2008
General Session
8:00 am
Welcome and introduction
Morton Coleman, MD
Myeloma Section
8:05 am
Introduction
Ruben Niesvizky, MD
Session I: Molecular biology of myeloma
Chair: Ajai Chari, MD
8:10 am
SNPs in MM: Lessons from MRC trials
Gareth J. Morgan, MD
8:30 am
Cell cycle dysregulation in myeloma: Basic science perspective
Selina Chen-Kiang, PhD
8:50 am
Genomics and the control of cell cycle
Leif Bergsagel, MD
9:10 am
Panel discussion
9:20 am
Break
Session II: Towards a risk adapted approach
Chair: Scott Ely, MD
9:40 am
Applying proteomics, genomics and cytogenetics to molecular prognostic models
Joseph Mikhael, MD
10:00 am
Evolving staging classifications and response criteria
Joan Blade, MD
10:20 am
What technique is best for determining MRD? And is it necessary?
Scott Ely, MD
10:35 am
Panel discussion
Session III: Treatment I
Chair: Tomer Mark, MD
10:45 am
Initial therapy: Case presentation with audience participation
Tomer Mark, MD
DEBATE I: Which initial therapy is best?
10:55 am
Initial therapy: Role of IMiDs compounds
Ruben Niesvizky, MD
11:10 am
Initial Therapy: Role of proteasome inhibitors
Ajai Chari, MD
11:25 am
Review of case and commentary
Tomer Mark, MD
11:30 am – 1:30 pm
Luncheon symposium
Session IV: Treatment II
Chair: TBD
DEBATE II: Is there a role for autologous transplant in MM?
1:30 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Bart Barlogie, MD, PhD
1:40 pm
Keynote Lecture: Lessons from Total Therapy:
Bart Barlogie, MD, PhD
DEBATE II: Is there a role for autologous transplant in MM?
2:05 pm
Pro: Jean Luc Harousseau, MD
2:20 pm
Con: Joan Blade, MD
2:35 pm
Is there a role for allogeneic transplant for the young in MM?
Sergio Giralt, MD
2:50 pm
Is there a role for combining chemotherapy with novel agents?
Kenneth C. Anderson, MD
3:55 pm
Novel agents and approaches currently evolving in MM
Kenneth C. Anderson, MD
3:05 pm
Novel agents and approaches currently evolving in MM
Kenneth C. Anderson, MD
3:20 pm
Panel discussion
3:30 pm
Break
Session V: Treatment III
Chair: Roger Pearse, MD
3:50 pm
Basic science meets the bone
Suzanne Lentzsch, MD, PhD
4:05 pm
Bisphosphonate pros and cons…and beyond
James Berenson, MD
4:20 pm
Debate: III: What bisphosphonate should be used and for how long?
Roundtable discussion
Roger Pearse, MD
James Berenson, MD
Suzanne Lentzsch, MD, PhD
4:35 pm
Adjourn
Friday, October 17, 2008
General Session
8:00 am
Welcome and introduction
Morton Coleman, MD
WM and CLL Section
8:05 am
Introduction
Richard R. Furman, MD
Session VI: Waldenstrom’s Macroglobulinemia
Chair: Richard Furman, MD
8:10 am
Biology and treatment of WM
Asher Chanan-Khan, MD
Session VII: CLL I
Chair: Richard Furman, MD
8:30 am
Chemistry of nucleoside analogs
Varsha Gandhi, PhD
8:45 am
What is the standard therapy for untreated patients with CLL?
Kanti Rai, MD
9:10 am
Feasible treatment options for relapsed CLL
Neil Kay, MD
9:30 am
Panel discussion
9:50 am
Break
Session VIII: CLL II
Chair: Susan O’Brien, MD
10:10 am
Targeted therapies in CLL
Richard Furman, MD
10:25 am
MRD: To achieve or not achieve?
Susan O’Brien, MD
10:45 am
Role of transplants in CLL
Issa Khouri, MD
11:00 am
Panel discussion
11:15 am – 1:15 pm
Luncheon symposium
Lymphoma Section
1:15 pm
Welcome and introduction
John Leonard, MD
Session IX: Lymphoma biology and imaging
Chair: Amy Chadburn, MD
1:20 pm
Prognosis in diffuse large B cell lymphoma
Izidore Lossos, MD
1:35 pm
Bcl-6 and DLBCL
Ari Melnick, MD
1:50 pm
Role of PET scanning in NHL, Hodgkin’s lymphoma and MM
Rebecca Elstrom, MD
2:10 pm
Panel discussion
2:20 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: John Ultmann Award for Contributions to Lymphoma
Research
Recipient: Joseph Bertino, MD
2:30 pm
Break
Session X: Aggressive lymphomas and Hodgkin’s disease
Chair: TBD
2:50 pm Update in the management of DLBCL
Thomas Habermann, MD
3:10 pm
Approach to primary CNS lymphoma
Lauren Abrey, MD
3:25 pm
Management of early stage Hodgkin’s disease
Leo I. Gordon, MD
3:55 pm
How do we treat relapsed/refractory LCL in the elderly?
Morton Coleman, MD
4:10 pm
Panel discussion
4:20 pm
Adjourn
Saturday, October 18, 2008
General Session
8:00 am
Welcome and introduction
Morton Coleman, MD
Session XI: Indolent and mantle cell lymphoma
Chair: Joseph Bertino, MD
8:05 am
Pathology of cutaneous lymphoma
Cynthia M. Magro, MD
8:20 am
Initial treatment for indolent lymphoma
Brian Link, MD
8:40 am
New strategies and agents for treatment of indolent lymphoma
Stephanie A. Gregory, MD
9:00 am
Role of auto and allo SCT for indolent lymphoma
Steve Forman, MD
9:20 am
Bendamustine: Is it a new old drug or just another alkylating agent?
Bruce Cheson, MD
9:40 am
Break
10:00 am
Update in the management in mantle cell lymphoma
John Leonard, MD
10:20 am
Maintenance rituximab: To give or not give?
Myron Czuczman, MD
10:40 am
Panel discussion
10:50 am
Break
Session XII: The best: Highlights from Lugano and submitted abstracts
Chair: Morton Coleman, MD
11:10 am
Highlights from the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland
Franco Cavalli, MD
11:40 am
Questions & answers
11:50 am
Oral abstract presentation
12:00 pm – 2:00 pm
Luncheon symposium
Session XIII: Lymphoma & myeloma agents in early development
2:00 pm
Novel agents in CLL
Neil Kay, MD
2:20 pm
Novel agents in relapsed/refractory large cell lymphoma
Sven De Vos, MD, PhD
2:40 pm
HDAC inhibitors and other novel agents in T-cell lymphoma
Francine Foss, MD
3:00 pm
Folate antagonists
Joseph Bertino, MD
3:15 pm
Syk inhibition
Jonathan Friedberg, MD
3:30 pm
Selective cyclin-dependent kinase inhibitors
Selina Chen-Kiang, PhD
3:45 pm
Anti-angiogenic therapies
Jia Ruan, MD
4:00 pm
Purine nucleoside phosphorylase inhibitors
Richard R. Furman, MD
4:15 pm
Congress conclusion and adjourn
New this year! Participants interested in presenting data should submit abstracts online by Friday, July 18, 2008. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final Summary Book and scheduled for oral or poster presentation.
Acceptance notifications and guidelines for poster presentation will be sent on Friday, August 29, 2008. Authors of accepted abstracts who have not registered will have until Thursday, October 2, 2008 to do so at the rate of $395.00. After this date, abstracts without registered presenters will be disregarded. Submit your abstract here.
Submission Deadline: Friday, July 18, 2008
Abstract Guidelines
-
Follow the online instructions
-
Abstracts must be written in English
-
Accepted format: Word document format, 9 point Arial font, 500 word count limit
-
Use a concise title
List affiliations of author(s) as briefly as possible, with city, state
and country
-
Place an asterisk (*) before the name of the presenting author
-
Use standard and well-accepted abbreviations
-
When using references, use standard and well-accepted formats
-
Abstract content should be single-spaced, typed in lower case
and contain:
-
Purpose of the study
-
Summarized description of the project
-
Results and conclusions
PHYSICIAN REGISTRATION FEES
Discounted (Physicians) . . . . . . . . $395
If payment received by August 14, 2008
Regular (Physicians) . . . . . . . . . . .$495
If payment received by October 9, 2008
Full/Onsite (Physicians) . . . . . . . . $595
To register after October 9, 2008
Nurses/Residents/Students*. . . . . . $99
*proof of eligibility must accompany registration
PHARMACIST* REGISTRATION FEES
Discounted . . . . . . . . . . . . . . . . $295
If payment received by August 14, 2008
Regular . . . . . . . . . . . . . . . . . . $345
If payment received by October 9, 2008
Full/Onsite * . . . . . . . . . . . . . . . $395
To register after October 9, 2008
*proof of eligibility must accompany registration
To register: You may register online by Thursday, October 9, 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: To register, registration and payment must be received no later than Thursday, October 9, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 9, 2008. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 9, 2008.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
HOTEL ACCOMMODATIONS
The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272
Reservation: (877) 476 8792
As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since 1893, The Waldorf=Astoria has epitomized the quintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.
SOLD OUT For the convenience of attendees, a limited number of rooms have been reserved until September 22, 2008 at a discounted rate of $389 single/double occupancy, plus tax, currently at 13.38% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 22, 2008.
SOLD OUT NEW: Additional Superior Guestrooms have been reserved until September 22, 2008 at a discounted rate of $435 single/double occupancy, plus tax, currently at 13.38% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the congress dates or after September 22, 2008.
To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2008 group. Internet users must enter the Group/Convention Code: LYA. Reservation requests received after September 22, 2008 may not be guaranteed the group rate.
Satellite Symposia
The agenda includes educational satellite symposia which we invite you to attend. All symposia will be held on the Starlight Rooftop, 18th floor.
Thursday, October 16, 2008
Course Chair
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.50 of AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologists, internists, oncologists, and other physicians, physicians-in-training, and other healthcare professionals (nurse practitioners, physician assistants, nurses, pharmacists) interested and/or involved in the care of patients with lymphoma and myeloma.
Educational Objectives
After successfully completing this continuing medical education activity, participants should be able to:
• Identify strategies that improve the recognition and management of patients with systemic amyloidosis
• Select the most appropriate pharmacotherapy regimen for patients with Waldenstrom’s macroglobulinemia
• Utilize emerging data to recommend induction therapies that achieve complete response and prolong survival in patients with multiple myeloma
Corporate Support
This educational activity is made possible by an unrestricted educational grant from:
|
Faculty
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Sundar Jagannath,MD
St. Vincent’s Comprehensive Cancer Center
New York, New York
Scientific Agenda
11:45 am
Introductions
11:50 am
Systemic amyloidosis: Recognizing & managing a treacherous disease
Raymond L. Comenzo, MD
12:10 pm
Waldenstrom’s macroglobulinemia: Who to treat, when to treat and how to treat
Sundar Jagannath, MD
12:30 pm Multiple myeloma: Complete response and prolonging survival through frontline therapeutic advances
Kenneth C. Anderson, MD
12:50 pm
Q & A
Friday, October 17, 2008
Course Chair
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.25 of AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologist, oncologist, internist, and other physicians, physicians in training and healthcare professionals involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.
Objectives
After successfully completing this continuing medical education activity, participants should be able to:
After successful completion of this educational activity, attendees should be able to:
• Discuss emerging therapies in the pipeline for the treatment of lymphoproliferative disorders
• Assess the emerging role of immunomodulatory agents in the treatment of multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma
• Interpret recent results with the use of immunomodulatory agents for the treatment of hematologic malignancies
• Identify future directions with the use of immunomodulatory agents in hematologic malignancies
Corporate Support
This meeting is made possible thanks to educational grants from:
|
Faculty
Asher A. Chanan-Khan, MD
Department of Medicine, School of Medicine Biomedical Science
Roswell Park Cancer Institute
Buffalo, New York
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
Paul A. Hamlin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York ]
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
Scientific Agenda
11:15
Assembly and Lunch
11:35
Introductions & opening remarks
Morton Coleman, MD
11:40 Exploring the mechanisms of activity of IMiD compounds
Asher Chanan-Khan, MD
11:55
Q&A
12:00
Evolution in the therapeutic landscape for multiple myeloma
Jeffrey A. Zonder, MD
12:15
Q&A
12:20
Emerging novel therapies for aggressive non-Hodgkins lymphomas
Paul A. Hamlin, MD
12:35
Q&A
12:40
Expanding the therapeutic options in CLL
Asher Chanan-Khan, MD
12:55
Q&A
1:00
Adjourn
Saturday, October 18, 2008
Course Chair
John P. Leonard, MD
Center for Lymphoma Myeloma
Weill Medical College of Cornell University
New York, New York
Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.50 of AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registration
Registration is complimentary to attendees of the Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies
Who Should Attend
This educational activity is specifically designed for hematologists, internists, oncologists, and other physicians, physicians-in-training, and other healthcare professionals (nurse practitioners, physician assistants, nurses, pharmacists) interested and/or involved in the care of patients with lymphoma and myeloma.
Educational Objectives
After successful completion of this educational activity, attendees should be able to:
• Describe the limitations of, and acquired resistance to, rituximab in patients with B-cell lymphomas
• Implement the best available regimens for patients with relapsed/refractory B-cell lymphomas
• Evaluate efficacy, toxicity and safety of the next generation anti-CD20 therapies for patients with B-cell lymphomas
• Discuss current trials and remaining questions these and future trials must address for improving outcomes in patients with B-cell lymphomas
Corporate Support
This meeting is made possible thanks to educational grants from:
|
Faculty
Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York
Peter W.M. Johnson, MD,FRCP
Southampton General Hospital
Southampton, United Kingdom
John P. Leonard, MD
Center for Lymphoma Myeloma
Weill Medical College of Cornell University
New York, New York
Brian K. Link, MD
Department of Internal Medicine Holden
comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa
Scientific Agenda
12:00 pm
Welcome
12:05 pm
Understanding rituximab resistance
Myron S. Czuczman, MD
12:25 pm
Current options for relapsed/refractory B-cell lymphomas
Peter W.M. Johnson, MD, FRCP
12:45 pm
Next generation anti-CD20 therapies for overcoming resistance in patients with B-cell lymphomas
Brian K.Link, MD
1:05 pm
Clinical trials in 2008 and beyond: Remaining questions
John P. Leonard, MD
1:25 pm
Chair summary and take home points
1:30 pm
Adjourn
Chair:
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
Co-Chair, Lymphoma Session
John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
Co-Chair, Myeloma Session
Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
Co-Chair, Leukemia Session
Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York
INVITATION
Dear Colleague,
It is our pleasure to invite you to join us at Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies. This fall's congress, October 16-18, 2008 at the Waldorf=Astoria in New York, New York, promises to be our most exciting and interactive meeting yet!
Since its inception in 2000, this congress has grown to nearly 800 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Using a dynamic approach, featuring clinical controversies, debates, and examinations of current treatment regimens, attendees will receive a thorough understanding of the evolution of thought and therapy of lymphoma and myeloma, as well as any significant developments which may lead to improved results.
Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.
Allowing attendees the benefit of visiting New York City during one of the most beautiful times of year, this congress will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world. We cordially welcome you to our fair city and promise to reward you with an exciting, informative congress!
Sincerely,
Morton Coleman, MD, Chair
John P. Leonard, MD, Co-Chair, Lymphoma Session
Ruben Niesvizky, MD, Co-Chair, Myeloma Session
Richard R. Furman, MD, Co-Chair, Leukemia Session
CONGRESS LOCATION and REGISTRATION:
The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272
The Registration and Information Desk will be staffed:
Thursday, October 16, 2008: 7:00 am – 4:30 pm
Friday, October 17, 2008: 7:30 am – 4:30 pm
Saturday, October 18, 2008: 7:30 am – 4:30 pm
Discounted Airfares
The Congress official agency, Williamsburg Travel Management can assist in making your arrangements.
Contact Judi Tarpley, CMP by telephone: +1 (770) 261-8613, toll free: + 1 888-232-9394 or by email judit@willtrav.com
ORGANIZER
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following companies have provided unrestricted educational grants in support of this Congress:
PLATINUM
Genentech BioOncology and Biogen Idec
GOLD
CORPORATE
EXHIBITOR
Lippincott, Williams & Wilkins
DONOR
|
Several options are available companies in this Congress. For more information, please contact Imedex at +1(770)751 7332, or by email at CME@imedex.com.